By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Roche NimbleGen said today that it plans to achieve compliance with Good Manufacturing Process standards for its microarrays "followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration."

Frank Pitzer, CEO of Roche NimbleGen, said in a statement that the company is in discussions with the FDA "to ensure compliance in our processes and products" in order to market its arrays in the diagnostic market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.